📊 ACLX Key Takeaways
Is Arcellx, Inc. (ACLX) a Good Investment?
Arcellx is a pre-commercial biotech company facing severe financial distress with massive operating losses, negative free cash flow of -$212.6M, and revenue declining 79.4% YoY, indicating potential clinical trial setbacks or delayed commercialization. The company is burning cash at an unsustainable rate with only $80.3M in cash reserves against $210.3M in annual operating cash burn, creating an imminent liquidity crisis within months. Without immediate major value-creating catalysts or significant capital raises, the company's financial runway appears critically short.
Arcellx’s fundamentals are weak: revenue fell 79.4% year over year while operating and net losses expanded sharply, producing deeply negative margins and returns on capital. Although the company still has strong near-term liquidity and no meaningful debt, the scale of operating cash burn relative to its cash balance materially weakens financial flexibility unless revenue recovers or external funding fills the gap.
Why Buy Arcellx, Inc. Stock? ACLX Key Strengths
- Adequate current ratio of 4.44x suggests near-term liquidity for operational needs
- No long-term debt obligation provides flexibility and avoids near-term refinancing risk
- Substantial stockholders equity of $402.4M represents remaining asset base
- Strong near-term liquidity with a 4.44x current and quick ratio
- Debt-free capital structure reduces solvency risk from leverage
- Positive equity base of $402.35M provides some balance sheet support
ACLX Stock Risks: Arcellx, Inc. Investment Risks
- Catastrophic revenue decline of 79.4% YoY with only $22.3M in current revenue indicates failed commercialization or trial failure
- Annual operating cash burn of $210.3M against $80.3M cash reserves means runway of less than 5 months at current burn rate
- Operating margin of -1135.6% and net margin of -1027.3% are unsustainable; company is pre-revenue/pre-profitability with massive R&D costs
- Negative free cash flow of -$212.6M demonstrates the company cannot sustain operations without external funding
- 14 Form 4 insider filings in 90 days may signal insider concerns or significant management transitions
- Revenue contraction of 79.4% YoY points to poor growth quality and weak commercialization traction
- Extreme negative profitability, including a -1135.6% operating margin and -1027.3% net margin
- Operating cash outflow of $210.26M and negative free cash flow of $212.59M suggest limited cash runway
Key Metrics to Watch
- Monthly cash burn rate and actual runway remaining until capital depletion
- Clinical trial results and regulatory pathway milestones for pipeline programs
- Revenue trends and commercial traction for any approved or approved-pending therapies
- Capital raise announcements or financing activities to extend runway
- Changes in insider ownership patterns and management retention
- Quarterly revenue trajectory and durability of collaboration/product revenue
- Operating cash burn relative to cash and equivalents
Arcellx, Inc. (ACLX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.44x current ratio provides a solid financial cushion.
ACLX Profit Margin, ROE & Profitability Analysis
ACLX vs Healthcare Sector: How Arcellx, Inc. Compares
How Arcellx, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Arcellx, Inc. Stock Overvalued? ACLX Valuation Analysis 2026
Based on fundamental analysis, Arcellx, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Arcellx, Inc. Balance Sheet: ACLX Debt, Cash & Liquidity
ACLX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Arcellx, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.47 indicates the company is currently unprofitable.
ACLX Revenue Growth, EPS Growth & YoY Performance
ACLX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.9M | -$7.2M | $-0.48 |
| Q2 2025 | $7.6M | -$7.2M | $-0.51 |
| Q1 2025 | $8.1M | -$7.2M | $-0.14 |
| Q3 2024 | $15.0M | -$7.2M | $-0.48 |
| Q2 2024 | $14.3M | -$7.2M | $-0.50 |
| Q1 2024 | $17.9M | -$7.2M | $-0.14 |
| Q3 2023 | $15.0M | -$23.9M | $-0.81 |
| Q2 2023 | $14.3M | -$23.9M | $-0.50 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Arcellx, Inc. Dividends, Buybacks & Capital Allocation
ACLX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Arcellx, Inc. (CIK: 0001786205)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACLX
What is the AI rating for ACLX?
Arcellx, Inc. (ACLX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACLX's key strengths?
Claude: Adequate current ratio of 4.44x suggests near-term liquidity for operational needs. No long-term debt obligation provides flexibility and avoids near-term refinancing risk. ChatGPT: Strong near-term liquidity with a 4.44x current and quick ratio. Debt-free capital structure reduces solvency risk from leverage.
What are the risks of investing in ACLX?
Claude: Catastrophic revenue decline of 79.4% YoY with only $22.3M in current revenue indicates failed commercialization or trial failure. Annual operating cash burn of $210.3M against $80.3M cash reserves means runway of less than 5 months at current burn rate. ChatGPT: Revenue contraction of 79.4% YoY points to poor growth quality and weak commercialization traction. Extreme negative profitability, including a -1135.6% operating margin and -1027.3% net margin.
What is ACLX's revenue and growth?
Arcellx, Inc. reported revenue of $22.3M.
Does ACLX pay dividends?
Arcellx, Inc. does not currently pay dividends.
Where can I find ACLX SEC filings?
Official SEC filings for Arcellx, Inc. (CIK: 0001786205) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACLX's EPS?
Arcellx, Inc. has a diluted EPS of $-4.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ACLX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Arcellx, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ACLX stock overvalued or undervalued?
Valuation metrics for ACLX: ROE of -56.9% (sector avg: 15%), net margin of -1,027.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ACLX stock in 2026?
Our dual AI analysis gives Arcellx, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACLX's free cash flow?
Arcellx, Inc.'s operating cash flow is $-210.3M, with capital expenditures of $2.3M. FCF margin is -953.9%.
How does ACLX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,027.3% (avg: 12%), ROE -56.9% (avg: 15%), current ratio 4.44 (avg: 2).